Advertisement
Canada markets close in 3 hours 44 minutes
  • S&P/TSX

    21,976.81
    +91.43 (+0.42%)
     
  • S&P 500

    5,101.80
    +53.38 (+1.06%)
     
  • DOW

    38,252.47
    +166.67 (+0.44%)
     
  • CAD/USD

    0.7312
    -0.0012 (-0.16%)
     
  • CRUDE OIL

    84.06
    +0.49 (+0.59%)
     
  • Bitcoin CAD

    86,820.06
    -759.59 (-0.87%)
     
  • CMC Crypto 200

    1,322.08
    -74.45 (-5.33%)
     
  • GOLD FUTURES

    2,347.20
    +4.70 (+0.20%)
     
  • RUSSELL 2000

    1,997.33
    +16.21 (+0.82%)
     
  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     
  • NASDAQ

    15,924.61
    +312.85 (+2.00%)
     
  • VOLATILITY

    15.35
    -0.02 (-0.13%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     

Akcea Therapeutics Investor Alert: Investigation on Behalf of Akca Shareholders

Boston, Massachusetts--(Newsfile Corp. - April 10, 2020) - Thornton Law Firm LLP, a law firm that represents shareholders in recovery actions, is investigating potential breach of fiduciary duty claims on behalf of shareholders of Akcea Therapeutics, Inc. (NASDAQ: AKCA).

FOR MORE INFORMATION: https://www.tenlaw.com/cases/AKCA

Akcea purports to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize products on a global basis. Akcea is a development and commercialization company focused on helping patients with serious diseases.

ADVERTISEMENT

The investigation arises from an analysis of pharmaceutical company Ionis, a majority, controlling stockholder of Akcea. In 2010, Ionis entered into a collaboration agreement with Glaxo Group Limited ("GSK"), pursuant to which Ionis would develop inotersen, an antisense drug for the treatment of ATTR amyloidosis ("ATTR"), and GSK would shoulder the research costs and share in the profits after inotersen's commercialization.

Investors who have purchased shares of Akcea and wish to learn more or discuss the issues surrounding the investigation are encouraged to contact the Thornton Law Firm's shareholder rights team at http://www.tenlaw.com/cases/AKCA, by email at shareholder@tenlaw.com, or calling 617-531-3917.

FOR MORE INFORMATION: https://www.tenlaw.com/cases/AKCA

Thornton Law Firm's securities attorneys are highly experienced in representing individual shareholders and institutional investors in recovering damages caused by violations of the securities laws. Its attorneys have established track records litigating securities cases in courts throughout the country and recovering losses on behalf of shareholders. This may be considered Attorney Advertising in some jurisdictions. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

CONTACT:

Thornton Law Firm LLP
State Street Financial Center
1 Lincoln Street
Boston, MA 02111
www.tenlaw.com/cases/AKCA

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/54341